tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Lehmann R et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. 2004 Am. J. Transplant. pmid:15196070
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Cavadas PC et al. Bilateral trans-humeral arm transplantation: result at 2 years. 2011 Am. J. Transplant. pmid:21521475
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Coghill AE et al. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. 2016 Am. J. Transplant. pmid:26824445
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
Zafrani L et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. 2009 Am. J. Transplant. pmid:19538494
Touzot M et al. Renal transplantation in HIV-infected patients: the Paris experience. 2010 Am. J. Transplant. pmid:20840478
Krämer BK et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. 2010 Am. J. Transplant. pmid:20840480
Trunečka P et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. 2010 Am. J. Transplant. pmid:20840481
Mehra MR et al. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. 2006 Am. J. Transplant. pmid:16686745
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Budde K et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. 2010 Am. J. Transplant. pmid:20121745
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Al-Massarani G et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. 2008 Am. J. Transplant. pmid:18925903
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Van Laecke S et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 2009 Am. J. Transplant. pmid:19624560
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Suwelack B et al. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. 2004 Am. J. Transplant. pmid:15023160
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Oetting WS et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. 2016 Am. J. Transplant. pmid:26485092
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Servais A et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. 2011 Am. J. Transplant. pmid:21672152
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Rostaing L et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23730730
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444